Pacira BioSciences (PCRX) Capital Expenditures (2010 - 2026)

Pacira BioSciences' Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 77.57% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $15.9 million, a 178.22% increase from a year earlier, with the FY2025 full-year figure at $15.3 million, up 175.53% from the prior year.
• Capital Expenditures advanced to $1.4 million in Q1 2026 per PCRX's latest filing, from $218000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $13.7 million in Q4 2023 and bottomed at -$3.0 million in Q4 2024.
• The 5-year median for Capital Expenditures is $3.8 million (2024), against an average of $4.0 million.
• Biggest YoY gain for Capital Expenditures was 2708.09% in 2024; the steepest drop was 121.57% in 2024.
• Year by year, Capital Expenditures stood at $5.5 million in 2022, then jumped by 149.29% to $13.7 million in 2023, then sank by 121.57% to -$3.0 million in 2024, then surged by 107.38% to $218000.0 in 2025, then surged by 524.77% to $1.4 million in 2026.
• Per Business Quant, the three latest PCRX Capital Expenditures figures stand at $1.4 million (Q1 2026), $218000.0 (Q4 2025), and $3.9 million (Q3 2025).